文献速递生殖医学

蛋白质组学分析揭示化疗诱导的人卵巢损伤的分子特征

Proteomic profiling reveals the molecular signatures of chemotherapy-induced human ovarian damage.
PubMed 文献 · Hum Reprod · 2025-01-01

研究比较了10例癌症患者冻存的卵巢皮质,其中5例在卵巢组织冷冻保存前接受过一线化疗,5例为年龄匹配对照,通过质谱、蛋白质印迹和免疫组化分析发现化疗暴露诱导卵泡DNA损伤和凋亡,并引起微环境改变包括免疫功能障碍、缺氧和凋亡增加、细胞周期和DNA修复能力受损及细胞外基质紊乱。

要点

  • 化疗暴露后卵泡凋亡(P=0.013)和DNA损伤(P=0.033)增加,但卵巢储备未耗竭。
  • 化疗暴露上调补体C3(P=0.032)、SELENBP1(P=0.030)和KRT18(P=0.015)表达。
  • 化疗暴露后基质细胞密度增加(1.84 ± 0.15 × 10^6 cells/mm3 vs. 1.62 ± 0.13 × 10^6 cells/mm3;P=0.036),但未观察到纤维化。

核心结论

  • 一线化疗暴露在卵巢组织冷冻保存前诱导卵泡DNA损伤和凋亡,并引起卵巢微环境改变包括免疫功能障碍、缺氧和凋亡增加、细胞周期和DNA修复能力受损及细胞外基质紊乱。

研究设计与样本

  • 分析10例癌症患者(年龄24-30岁)为研究目的捐赠的冻存卵巢皮质样本,其中5例在卵巢组织冷冻保存前接受过一线化疗,5例为年龄匹配未化疗对照。

主要发现

  • 在化疗暴露和对照卵巢中检测到5209种蛋白质,其中237种(4.5%)差异表达。
  • 化疗暴露后免疫应答、缺氧和凋亡相关生物学通路上调,细胞周期和DNA修复相关通路下调,细胞外基质网络标志物失调。
  • 蛋白质印迹和免疫染色证实化疗暴露后补体C3(先天免疫;P=0.032)、SELENBP1(缺氧;P=0.030)和KRT18(凋亡;P=0.015)显著上调,SERPIN A3(细胞外基质;P=0.077)非显著增加,NCBP2(DNA修复)降低但未达显著(P=0.067)。
  • 化疗后基质细胞密度增加(1.84 ± 0.15 × 10^6 cells/mm3 vs. 1.62 ± 0.13 × 10^6 cells/mm3;P=0.036),但未观察到纤维化;基质凋亡和氧化应激水平两组相当(P=0.464和P=0.247)。
  • 一线化疗持续影响生殖细胞,增加卵泡凋亡(P=0.013)、DNA损伤(P=0.033)和可能的形态缺陷(P=0.061),但未耗竭卵巢储备。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 既往暴露于化疗的患者在卵巢组织冷冻保存前不同时间接受了不同的低性腺毒性化疗方案,难以分离单个药物的效应或区分短期和长期失调的生物学过程。
  • 分析在小队列中进行,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does first-line chemotherapy alter follicular survival and the ovarian microenvironment? SUMMARY ANSWER: First-line chemotherapy exposure prior to ovarian tissue cryopreservation (OTC) induces follicular DNA damage and apoptosis, and causes microenvironmental alterations including immune dysfunction, increased hypoxia and apoptosis, impaired cell cycle and DNA repair capacity, and disruption of the extracellular matrix (ECM). WHAT IS KNOWN ALREADY: Although the mechanisms underlying chemotherapy-induced damage to germ cells are being increasingly deciphered, its impact on the ovarian microenvironment remains largely unexplored. The ovarian stroma is equally exposed to chemotherapy, and since its cells and components are in active communication with follicles, any microenvironmental changes induced by chemotherapy might affect follicles as well. STUDY DESIGN, SIZE, DURATION: Cryopreserved ovarian cortex samples from 10 cancer patients (aged 24-30 years) who donated tissue for research purposes were analyzed. Of the 10 patients, 5 had received first-regimen chemotherapy and 5 age-matched controls had not undergone chemotherapy prior to OTC. Chemotherapy-induced ovarian injury was evaluated by comparing stromal and follicular alterations between chemotherapy-exposed and control patients. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cryopreserved ovarian cortex were processed directly after thawing. Proteins and biological processes dysregulated in response to chemotherapy were identified by mass spectrometry, and the data obtained were validated by western blotting and immunohistochemistry. Stromal and follicular alterations were further examined by (immuno)histochemistry, focusing on apoptosis (TUNEL), DNA damage (γH2Ax), oxidative stress (8-OHdG), proliferation (Ki67), fibrosis (picrosirius red), and analysis of follicle number, developmental stage and morphology. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 5209 proteins were detected in both chemotherapy-exposed and control ovaries, of which 237 proteins (4.5%) showed differential expression. Biological pathways related to immune response, hypoxia and apoptosis were upregulated after chemotherapy exposure, while those involved in cell cycle and DNA repair were downregulated. Markers of the ECM network were also dysregulated. Western blotting and immunostaining confirmed the significant upregulation of complement C3 (innate immunity; P = 0.032), SELENBP1 (hypoxia; P = 0.030) and KRT18 (apoptosis; P = 0.015) as well as a non-significant increase in SERPIN A3 level (ECM; P = 0.077) following chemotherapy-exposure, while NCBP2 (DNA repair) was reduced, though not significantly (P = 0.067). Targeted analyses demonstrated that despite increased stromal cell density following chemotherapy treatment (1.84 ± 0.15 × 106 cells/mm3 vs. 1.62 ± 0.13 × 106 cells/mm3; P = 0.036), no fibrosis was observed. Stromal apoptosis and oxidative stress levels were comparable in both groups (P = 0.464 and P = 0.247, respectively). In contrast, first-regimen chemotherapy persistently affected germ cells, increasing follicular apoptosis (P = 0.013), DNA damage (P = 0.033) and possibly morphological defects (P = 0.061), without depleting the ovarian reserve. LIMITATIONS, REASONS FOR CAUTION: Patients previously exposed to chemotherapy had received different low-gonadotoxic chemotherapy regimens at different times before OTC, making it challenging to isolate the effects of individual agents or to differentiate between short- and long-term dysregulated biological processes. Additionally, analyses were performed on a small cohort and results should be interpreted cautiously. WIDER IMPLICATIONS OF THE FINDINGS: These findings provide evidence that chemotherapy significantly alters both the ovarian germ cells and stroma, emphasizing the need to further investigate the underlying molecular mechanisms and their impact on ovarian function and fertility preservation. They also suggest target proteins which may drive these chemotherapy-associated ovarian damage for future investigations. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by a grant from the Fond National de la Recherche Scientifique de Belgique-FNRS (grant 1.B.218.24F awarded to J.G.). The support is provided by the Funds Suzanne Duchesne, Serge Rousseau and Docteur Jean Gérard, managed by the King Baudouin Foundation, and by the Jaumotte-Demoulin Foundation. The CMMI is supported by the European Regional Development Fund and the Walloon Region. J.G. and I.D. are supported by FNRS as a postdoctoral researcher and a senior research associate, respectively. The authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Grosbois J, Bisteau X, Imbault V, et al. Proteomic profiling reveals the molecular signatures of chemotherapy-induced human ovarian damage. Hum Reprod. 2025. PMID: 41206366. doi:10.1093/humrep/deaf203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。